DK3255062T3 - Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl) - Google Patents
Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl) Download PDFInfo
- Publication number
- DK3255062T3 DK3255062T3 DK17177583.6T DK17177583T DK3255062T3 DK 3255062 T3 DK3255062 T3 DK 3255062T3 DK 17177583 T DK17177583 T DK 17177583T DK 3255062 T3 DK3255062 T3 DK 3255062T3
- Authority
- DK
- Denmark
- Prior art keywords
- cutant
- diagnostication
- ptcl
- peripheral
- cell lymphoma
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361764639P | 2013-02-14 | 2013-02-14 | |
| US201361831792P | 2013-06-06 | 2013-06-06 | |
| EP14704576.9A EP2956482B1 (en) | 2013-02-14 | 2014-02-13 | Treatment of peripheral t cell lymphoma |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3255062T3 true DK3255062T3 (da) | 2019-10-07 |
Family
ID=50112904
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14704576.9T DK2956482T3 (da) | 2013-02-14 | 2014-02-13 | Behandling af perifert t-cellelymfom |
| DK17177583.6T DK3255062T3 (da) | 2013-02-14 | 2014-02-13 | Anti-nkp46-antistof til diagnosticering af et ikke-kutant perifert t-cellelymfom (ptcl) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14704576.9T DK2956482T3 (da) | 2013-02-14 | 2014-02-13 | Behandling af perifert t-cellelymfom |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10344087B2 (da) |
| EP (2) | EP2956482B1 (da) |
| DK (2) | DK2956482T3 (da) |
| ES (2) | ES2747920T3 (da) |
| WO (1) | WO2014125041A1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014125041A1 (en) * | 2013-02-14 | 2014-08-21 | Innate Pharma | Treatment of peripheral t cell lymphoma |
| WO2016030488A1 (en) * | 2014-08-27 | 2016-03-03 | Innate Pharma | Treatment of celiac disease |
| EP3325967B1 (en) | 2015-07-24 | 2019-12-04 | Innate Pharma | Methods for detecting tissue infiltrating nk cells |
| CA3007898A1 (en) * | 2015-12-28 | 2017-07-06 | Innate Pharma | Variable regions for nkp46 binding proteins |
| WO2018032088A2 (en) * | 2016-08-17 | 2018-02-22 | University Health Network | Regulation of tumor-associated t cells |
| JP2020501506A (ja) * | 2016-09-07 | 2020-01-23 | イッサム リサーチ デベロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー. | 抗NKp46抗体およびその治療的使用 |
| WO2018073363A1 (en) | 2016-10-21 | 2018-04-26 | Innate Pharma | Treatment with anti-kir3dl2 agents |
| AU2018213823B2 (en) * | 2017-01-24 | 2024-11-07 | Innate Pharma | NKp46 binding agents |
| CN111316101B (zh) * | 2017-05-19 | 2023-11-10 | 皇家墨尔本理工大学 | 预测对环磷酰胺疗法的反应者 |
| CN112384534A (zh) | 2018-05-21 | 2021-02-19 | 指南针制药有限责任公司 | 用于增强nk细胞对靶细胞的杀死的组合物和方法 |
| US12686725B2 (en) | 2020-05-05 | 2026-07-21 | Mythic Therapeutics, Inc. | Anti-DLL3 antibodies and methods of use |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5776427A (en) | 1992-03-05 | 1998-07-07 | Board Of Regents, The University Of Texas System | Methods for targeting the vasculature of solid tumors |
| AU717020B2 (en) | 1996-05-03 | 2000-03-16 | Immunomedics Inc. | Targeted combination immunotherapy of cancer |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| PL213948B1 (pl) | 2001-10-25 | 2013-05-31 | Genentech Inc | Kompozycje zawierajace glikoproteine, czasteczka kwasu nukleinowego kodujaca te glikoproteine, komórka gospodarza, sposób wytwarzania glikoproteiny, kompozycja do zastosowania do leczenia, zastosowanie kompozycji i zestaw zawierajacy kompozycje |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| KR20050000380A (ko) | 2002-04-09 | 2005-01-03 | 교와 핫꼬 고교 가부시끼가이샤 | 게놈이 개변된 세포 |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| US20060235208A1 (en) * | 2002-09-27 | 2006-10-19 | Xencor, Inc. | Fc variants with optimized properties |
| US20050058661A1 (en) | 2002-10-18 | 2005-03-17 | Sykes Kathryn F. | Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus Borrelia |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| DE10324108B3 (de) | 2003-05-21 | 2005-01-27 | Aesculap Ag & Co. Kg | Wirbelkörperersatzimplantat |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1747237A4 (en) | 2004-04-16 | 2008-05-21 | Macrogenics Inc | SPECIFIC GAMMA FC ANTIBODIES AND METHODS OF USING THE SAME |
| CA2565874C (en) | 2004-05-10 | 2017-10-03 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| KR20080032065A (ko) | 2005-06-03 | 2008-04-14 | 제넨테크, 인크. | 푸코실화 수준이 조절된 항체의 생성 방법 |
| DK2573114T3 (da) | 2005-08-10 | 2016-07-04 | Macrogenics Inc | Identificering og fremstilling af antistoffer med en variant af Fc-regioner og fremgangsmåder til anvendelse af samme |
| EP1934260B1 (en) * | 2005-10-14 | 2017-05-17 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| AU2012202895A1 (en) * | 2005-10-14 | 2012-06-07 | Innate Pharma | Compositions and methods for treating proliferative disorders |
| FR2894982A1 (fr) | 2005-12-16 | 2007-06-22 | Lab Francais Du Fractionnement | Procede de preparation d'anticorps selectifs des recepteurs fc activateurs |
| MX2008009220A (es) | 2006-01-17 | 2008-10-10 | Biolex Therapeutics Inc | Composiciones y metodos para la humanizacion y optimizacion de n-glicanos en plantas. |
| JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス,インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| CA2660592C (en) | 2006-05-26 | 2016-07-12 | Macrogenics, Inc. | Humanized fc.gamma.riib-specific antibodies and methods of use thereof |
| EP2032159B1 (en) | 2006-06-26 | 2015-01-07 | MacroGenics, Inc. | Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof |
| EP1878747A1 (en) | 2006-07-11 | 2008-01-16 | greenovation Biotech GmbH | Glyco-engineered antibodies |
| EP1995309A1 (en) | 2007-05-21 | 2008-11-26 | Vivalis | Recombinant protein production in avian EBx® cells |
| WO2011086179A1 (en) * | 2010-01-15 | 2011-07-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for diagnosis and treatment of cutaneous t cell lymphomas |
| DK2542256T3 (da) | 2010-03-04 | 2019-08-26 | Macrogenics Inc | Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf |
| WO2012175613A1 (en) * | 2011-06-21 | 2012-12-27 | Innate Pharma | NKp46-MEDIATED NK CELL TUNING |
| WO2014125041A1 (en) * | 2013-02-14 | 2014-08-21 | Innate Pharma | Treatment of peripheral t cell lymphoma |
-
2014
- 2014-02-13 WO PCT/EP2014/052849 patent/WO2014125041A1/en not_active Ceased
- 2014-02-13 ES ES17177583T patent/ES2747920T3/es active Active
- 2014-02-13 DK DK14704576.9T patent/DK2956482T3/da active
- 2014-02-13 EP EP14704576.9A patent/EP2956482B1/en active Active
- 2014-02-13 ES ES14704576.9T patent/ES2637151T3/es active Active
- 2014-02-13 DK DK17177583.6T patent/DK3255062T3/da active
- 2014-02-13 EP EP17177583.6A patent/EP3255062B1/en active Active
- 2014-02-13 US US14/767,600 patent/US10344087B2/en active Active
-
2019
- 2019-06-25 US US16/451,051 patent/US11999784B2/en active Active
-
2024
- 2024-06-03 US US18/731,443 patent/US20240425586A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3255062B1 (en) | 2019-07-03 |
| DK2956482T3 (da) | 2017-10-16 |
| ES2747920T3 (es) | 2020-03-12 |
| EP2956482A1 (en) | 2015-12-23 |
| US20150376274A1 (en) | 2015-12-31 |
| US10344087B2 (en) | 2019-07-09 |
| EP3255062A1 (en) | 2017-12-13 |
| US11999784B2 (en) | 2024-06-04 |
| ES2637151T3 (es) | 2017-10-11 |
| US20240425586A1 (en) | 2024-12-26 |
| EP2956482B1 (en) | 2017-06-28 |
| US20190315857A1 (en) | 2019-10-17 |
| WO2014125041A1 (en) | 2014-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245573B (en) | Cell | |
| IL242253A (en) | Electro-chemical filter apparatus | |
| DK3042411T3 (da) | Metalunderstøttet fastoxidbrændselscelle | |
| PL2970441T3 (pl) | POLIPEPTYDY ZAWIERAJĄCE AGLIKOZYLOWANY Fc | |
| DK3043816T3 (da) | Anti-b7-h1-antistoffer til behandling af tumorer | |
| DK3537097T3 (da) | Indretning til udformning af riller i rørelementer | |
| DK3812453T3 (da) | Metabolisk optimeret cellkultur | |
| DK3336106T3 (da) | Anti-fcrh5-antistoffer | |
| DK2992020T3 (da) | Cs1-specifik kimær antigenreceptor-manipulerede immuneffektorceller | |
| DK3708583T3 (da) | Ikke-fucosylerede anti-fgfr2iiib-antistoffer | |
| EP2988346A4 (en) | CELL HOUSING | |
| DK3068800T3 (da) | FcRn-specifikke antistoffer | |
| EP3066193C0 (en) | CELL CULTURE PROCESS | |
| IL240626A0 (en) | Social context for applications | |
| DK3680000T3 (da) | Fremgangsmåder til oprensning af antistoffer | |
| FI20135168L (fi) | Tekniikoita matkaviestinsovellusten räätälöintiä varten | |
| KR20180084767A (ko) | 휴대폰 하우징 적용을 위한 폴리카보네이트-폴리실록산 공중합체 조성물 | |
| HRP20190085T1 (hr) | Anti-cd52 protutijela | |
| DK2983680T3 (da) | Forbedring af organer til transplantation | |
| EP3067906A4 (en) | ELECTROCHEMICAL DEVICE | |
| DK3065774T3 (da) | Anti-CCL17-antistoffer | |
| FR3013901B1 (fr) | Dispositif electrochimique autophotorechargeable | |
| EP3067936A4 (en) | SOLAR CELL | |
| DK3042205T3 (da) | Fremgangsmåde til forbedring af antistofstabilitet | |
| DE112013007428A5 (de) | Komponententräger |